Approach to the Patient With Prolactinoma.
Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R.
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174.
Treatment of Prolactinoma.
Inder WJ, Jang C.
Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095.
Prolactinoma in postmenopausal women: a systematic review.
Carneiro MS, de Mira TAA, Yela DA, Benetti-Pinto CL.
Menopause. 2024 Feb 1;31(2):160-167. doi: 10.1097/GME.0000000000002303. Epub 2024 Jan 9.
Diagnosis and Management of Pituitary Adenomas: A Review.
Tritos NA, Miller KK.
JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444.
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma.
Wan X, Yan Z, Tan Z, Cai Z, Qi Y, Lu L, Xu Y, Chen J, Lei T.
Neuroendocrinology. 2022;112(5):417-426. doi: 10.1159/000517356. Epub 2021 May 25.
[Prolactinoma].
Krysiak R, Okopień B, Marek B, Szkróbka W.
Przegl Lek. 2009;66(4):198-205.
Prolactinoma through the female life cycle.
Cocks Eschler D, Javanmard P, Cox K, Geer EB.
Endocrine. 2018 Jan;59(1):16-29. doi: 10.1007/s12020-017-1438-7. Epub 2017 Nov 24.
Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D.
Neuroendocrinology. 2019;109(1):42-50. doi: 10.1159/000495775. Epub 2019 Mar 18.
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S.
Lancet Diabetes Endocrinol. 2025 Oct;13(10):874-890. doi: 10.1016/S2213-8587(25)00227-X. Epub 2025 Aug 25.
Hyperprolactinemia and prolactinoma.
Romijn JA.
Handb Clin Neurol. 2014;124:185-95. doi: 10.1016/B978-0-444-59602-4.00013-7.
